无虹膜相关角膜病变模型的转录组分析与度洛西汀疗效评估
研究对17只Pax6+/-小眼小鼠和10只野生型小鼠角膜进行转录组分析,发现淋巴管生成、炎症及角化相关基因失调;10 µM度洛西汀滴眼每日两次90天未能逆转已形成的病变,但转录组显示其抑制炎症基因并促进抗炎保护活性。
要点
- AAK小鼠角膜转录组显示Ccl21家族、炎症及角化基因上调,药物代谢基因下调。
- 度洛西汀滴眼90天未改善成年小鼠已建立的AAK临床表型。
- 度洛西汀在转录组水平抑制炎症基因并调节药物代谢,提示潜在获益。
核心结论
- 转录组揭示AAK小鼠模型多条未探索通路和基因改变,度洛西汀当前方案未改善已建立病变但具潜在治疗价值。
研究设计与样本
- 17只4月龄Pax6+/-小眼小鼠(p.Gly208*突变)与10只野生型129S1/SvImJ小鼠用于转录组分析。
- 度洛西汀10 µM滴眼每日两次90天,通过微阵列、Western blot和免疫染色评估。
主要发现
- 角膜转录组富集与淋巴管生成相关的Ccl21基因家族成员。
- 炎症、细胞黏附、分化、运动和角化相关基因上调,药物代谢基因下调。
- 显著失调基因包括Gpha2、Chrnb3、Epgn、Cnfn、激肽释放酶及炎症介质Il18r1和经典补体因子。
临床怎么用
- 度洛西汀当前滴眼方案不适用于改善已建立的AAK,需进一步研究其治疗潜力。
- 转录组鉴定的失调基因如Gpha2、Chrnb3等可作为未来治疗靶点探索方向。
局限性
- 度洛西汀仅评估一种浓度和给药方案,未测试其他剂量或早期干预。
- 研究为动物模型,结果向人类AAK转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Aniridia-associated keratopathy (AAK) leads to loss of corneal transparency because of epithelial, inflammatory, and pathological vascular changes. Here, we sought to understand this process at the transcriptomic level while evaluating an experimental pharmacotherapy for potential modulatory effects. METHOD: 17 Pax6+/- Small-eye (Sey) heterozygous mice with p.Gly208* Pax6 mutation and 10 wild-type 129S1/SvImJ mice at four months of age were examined to identify dysregulated genes and pathways in established AAK. We next evaluated the potential efficacy of 10 µM duloxetine administered as eye drops twice daily for 90 days, assessing outcomes at the transcriptomic level via microarray and protein level with Western blot and immunostaining. RESULTS: Transcriptomic analysis of the cornea revealed enrichment of Ccl21 gene family members associated with lymphangiogenesis, along with upregulation of genes involved in inflammation, cell adhesion, differentiation, motility, and keratinization, and downregulation of drug metabolism with significantly dysregulated genes emerging as potential therapeutic targets, including Gpha2, Chrnb3, Epgn, Cnfn, kallikreins and inflammation mediators Il18r1 and classical complement factors. Duloxetine therapy failed to regress AAK in adult corneas; however, transcriptomic profiling indicated duloxetine suppressed inflammatory genes and promoted anti-inflammatory and protective activity while modulating drug metabolism, suggesting potential beneficial effects in the cornea. CONCLUSIONS: Transcriptomics reveals multiple unexplored pathways and genes altered in the AAK mouse model. Although clinical results with duloxetine are promising, our current regimen and delivery method did not improve established disease. Duloxetine's therapeutic potential requires further study.
引用
- Javidjam D, Moustardas P, Dashti A, et al. Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy. Invest Ophthalmol Vis Sci. 2026. PMID: 41543334. doi:10.1167/iovs.67.1.37
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。